155 related articles for article (PubMed ID: 38511030)
21. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
Kim KI; Lee KH; Kim TR; Chun YS; Lee TH; Park HK
J Breast Cancer; 2014 Mar; 17(1):40-6. PubMed ID: 24744796
[TBL] [Abstract][Full Text] [Related]
22. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
23. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
25. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
26. A Novel Model Incorporating Tumor Stiffness, Blood Flow Characteristics, and Ki-67 Expression to Predict Responses After Neoadjuvant Chemotherapy in Breast Cancer.
Zhang J; Gao S; Zheng Q; Kang Y; Li J; Zhang S; Shang C; Tan X; Ren W; Ma Y
Front Oncol; 2020; 10():603574. PubMed ID: 33364197
[TBL] [Abstract][Full Text] [Related]
27. Determinants of pathological complete response to neoadjuvant chemotherapy in breast cancer: A single-institution experience.
Joshi S; Chougle Q; Noronha J; Hawaldar R; Nair N; Vanmali V; Parmar V; Thakkar P; Chitkara G; Shet T; Badwe RA
Indian J Cancer; 2023 Feb; ():. PubMed ID: 36861728
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
29. Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer.
Lin Q; Liu Y; Chen H; Liu Y; Tang Q; Liu J; Chen H
Mol Clin Oncol; 2013 Sep; 1(5):839-844. PubMed ID: 24649257
[TBL] [Abstract][Full Text] [Related]
30. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
[TBL] [Abstract][Full Text] [Related]
31. Quantitative intravoxel incoherent motion parameters derived from whole-tumor volume for assessing pathological complete response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Xu Q; Xu Y; Sun H; Chan Q; Shi K; Song A; Wang W
J Magn Reson Imaging; 2018 Jul; 48(1):248-258. PubMed ID: 29281151
[TBL] [Abstract][Full Text] [Related]
32. A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma.
Kunnuru SKR; Thiyagarajan M; Martin Daniel J; Singh K B
Breast Cancer (Dove Med Press); 2020; 12():259-266. PubMed ID: 33262647
[TBL] [Abstract][Full Text] [Related]
33. Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer.
Tewari M; Pradhan S; Singh U; Singh TB; Shukla HS
Asian J Surg; 2010 Oct; 33(4):157-67. PubMed ID: 21377101
[TBL] [Abstract][Full Text] [Related]
34. Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study.
Tang L; Shu X; Tu G
World J Surg Oncol; 2022 Jan; 20(1):27. PubMed ID: 35093083
[TBL] [Abstract][Full Text] [Related]
35. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
36. Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care centre experience.
Bhattacharyya T; Sharma SC; Yadav BS; Singh R; Singh G
Indian J Med Paediatr Oncol; 2014 Jul; 35(3):215-20. PubMed ID: 25336793
[TBL] [Abstract][Full Text] [Related]
37. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
[TBL] [Abstract][Full Text] [Related]
38. Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
Chatterjee S; Saha A; Arun I; Nayak SS; Sinha S; Agrawal S; Parihar M; Ahmed R
Breast Cancer (Dove Med Press); 2015; 7():381-8. PubMed ID: 26677343
[TBL] [Abstract][Full Text] [Related]
39. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer.
Eryilmaz MK; Mutlu H; Ünal B; Salim DK; Musri FY; Coşkun HŞ
J Cancer Res Ther; 2018; 14(3):619-624. PubMed ID: 29893329
[TBL] [Abstract][Full Text] [Related]
40. Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy.
Değerli E; Şentürk Öztaş N; Alkan G; Bedir Ş; Derin S; Valıkhanova N; Saraç B; Kacar E; Demirci NS; Demirelli HF; Turna H
J Chemother; 2023 Feb; 35(1):29-38. PubMed ID: 35220928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
